Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014

Vaccine

Volumn 33, Issue 26, 2015, Pages 3047-3055

  Kaufmann, Stefan H E ^a   Bloom, Barry ^a   Brosch, Roland ^a   Cardona, Pere Joan ^a   Dockrell, Hazel ^a   Fritzell, Bernard ^a   Grode, Leander ^a   Hanekom, Willem ^a   Hokey, David ^a   Levin, Michael ^a   Martín, Carlos ^a   Sander, Peter ^a   Scriba, Thomas ^a   Shaligram, Umesh ^a   Tameris, Michele ^a   von Reyn, Fordham ^a   Walker, Barry ^a   Weiner, January ^a   White, Richard G ^a   Schrager, Lewis ^a  

^a AERAS   (United States)

Author keywords

BCG; Live, Attenuated vaccine; Mycobacterium tuberculosis; Tuberculosis vaccine; Whole cell killed vaccine

Indexed keywords

BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; MYCOBACTERIA CELL VACCINE; UNCLASSIFIED DRUG;

BCG VACCINATION; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DELETION MUTANT; FRANCE; GERMANY; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MACROPHAGE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SWITZERLAND; TUBERCULOSIS; WHOLE CELL; ADOLESCENT; ADULT; ANIMAL; DRUG DESIGN; FEMALE; IMMUNOLOGY; VACCINATION;

ADOLESCENT; ADULT; ANIMALS; BCG VACCINE; DRUG DESIGN; FEMALE; GERMANY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84930536730     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.056     Document Type: Conference Paper

References (70)

1. WHO Global tuberculosis report 2014 2014, WHO.
2. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 2009, 106:13980-13985.
3. Knight G.M., Griffiths U.K., Sumner T., Laurence Y.V., Gheorghe A., Vassall A., et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A 2014, 111:15520-15525.
4. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013, 34:271-286.
5. Anderson S.T., Kaforou M., Brent A.J., Wright V.J., Banwell C.M., Chagaluka G., et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014, 370:1712-1723.
6. Weiner J., Kaufmann S. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 2014, 275:467-480.
7. Comas I., Chakravartti J., Small P.M., Galagan J., Niemann S., Kremer K., et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010, 42:498-503.
8. Kaufmann S.H., Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012, 23:900-907.
9. Kaufmann S.H., Winau F. From bacteriology to immunology: the dualism of specificity. Nat Immunol 2005, 6:1063-1066.
10. Calmette A., Guérin C., Boquet A., Nègre L. La vaccination préventive contre la tuberculose par le BCG 1927, Masson et cie.
11. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
12. WHO. BCG vaccine.
13. Checkley A.M., Wyllie D.H., Scriba T.J., Golubchik T., Hill A.V., Hanekom W.A., et al. Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses. PLoS ONE 2011, 6:e26434.
14. Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clini Infect Dis 2014, 58:470-480.
15. Jenkins H.E., Tolman A.W., Yuen C.M., Parr J.B., Keshavjee S., Perez-Velez C.M., et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014.
16. Hesseling A.C., Marais B.J., Gie R.P., Schaaf H.S., Fine P.E., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25:14-18.
17. Mahairas G.G., Sabo P.J., Hickey M.J., Singh D.C., Stover C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996, 178:1274-1282.
18. Pym A.S., Brodin P., Brosch R., Huerre M., Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002, 46:709-717.
19. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003, 9:533-539.
20. Hsu T., Hingley-Wilson S.M., Chen B., Chen M., Dai A.Z., Morin P.M., et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A 2003, 100:12420-12425.
21. de Jonge M.I., Brosch R., Brodin P., Demangel C., Cole S.T. Tuberculosis: from genome to vaccine. Expert Rev Vaccines 2005, 4:541-551.
22. van der Wel N., Hava D., Houben D., Fluitsma D., van Zon M., Pierson J., et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129:1287-1298.
23. Simeone R., Bobard A., Lippmann J., Bitter W., Majlessi L., Brosch R., et al. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog 2012, 8:e1002507.
24. Ryan A.A., Nambiar J.K., Wozniak T.M., Roediger B., Shklovskaya E., Britton W.J., et al. Antigen load governs the differential priming of CD8T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. J Immunol 2009, 182:7172-7177.
25. Majlessi L., Prados-Rosales R., Casadevall A., Brosch R. Release of mycobacterial antigens. Immunol Rev 2015, 264:25-45.
26. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Eddine A.N., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Investig 2005, 115:2472.
27. Kaufmann S.H., Cotton M.F., Eisele B., Gengenbacher M., Grode L., Hesseling A.C., et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 2014, 13:619-630.
28. Rechsteiner M., Rogers S.W. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996, 21:267-271.
29. Decatur A.L., Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290:992-995.
30. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H. Recombinant BCG δureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 10.1093/infdis/jir592.
31. Farinacci M., Weber S., Kaufmann S.H. The recombinant tuberculosis vaccine rBCG δureC:: hly+ induces apoptotic vesicles for improved priming of CD4+ and CD8+ T cells. Vaccine 2012, 30:7608-7614.
32. Vogelzang A., Perdomo C., Zedler U., Kuhlmann S., Hurwitz R., Gengenbacher M., et al. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin δureC:: hly vaccine's superior protection against tuberculosis. J Infect Dis 2014, 210:1928-1937.
33. Saiga H., Nieuwenhuizen N., Gengenbacher M., Koehler A.-B., Schuerer S., Moura-Alves P., et al. The recombinant BCG δureC:: hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. J Infect Dis 2014.
34. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., Kaufmann S.H. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A 1998, 95:5299-5304.
35. Kaufmann S.H. Learning from natural infection for rational tuberculosis vaccine design: from basic science to translational research. Hum Vaccines 2010, 6:614-618.
36. Grode L., Ganoza C.A., Brohm C., Weiner J., Eisele B., Kaufmann S.H. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013, 31:1340-1348.
37. Arbues A., Aguilo J.I., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013, 31:4867-4873.
38. Kamath A.T., Fruth U., Brennan M.J., Dobbelaer R., Hubrechts P., Ho M.M., et al. New live mycobacterial vaccines: the Geneva Consensus on essential steps towards clinical development. Vaccine 2005, 23:3753-3761.
39. Walker K., Brennan M., Ho M., Eskola J., Thiry G., Sadoff J., et al. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010, 28:2259-2270.
40. Gonzalo-Asensio J., Mostowy S., Harders-Westerveen J., Huygen K., Hernández-Pando R., Thole J., et al. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS ONE 2008, 3:e3496.
41. Aguilo J., Alonso H., Uranga S., Marinova D., Arbues A., Martino A., et al. ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis. Cell Microbiol 2013, 15:1994-2005.
42. Solans L., Gonzalo-Asensio J., Sala C., Benjak A., Uplekar S., Rougemont J., et al. The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis. PLoS Pathog 2014, 10:e1004183.
43. Nambiar J.K., Pinto R., Aguilo J.I., Takatsu K., Martin C., Britton W.J., et al. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol 2012, 42:385-392.
44. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 2009, 4:e5264.
45. Waddell R.D., Chintu C., Lein A.D., Zumla A., Karagas M.R., Baboo K.S., et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000, 30(Suppl. 3):S309-S315.
46. Vuola J.M., Ristola M.A., Cole B., Jarviluoma A., Tvaroha S., Ronkko T., et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003, 17:2351-2355.
47. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24:675-685.
48. Lahey T., Arbeit R.D., Bakari M., Horsburgh C.R., Matee M., Waddell R., et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 2010, 28:7652-7658.
49. Groschel M.I., Prabowo S.A., Cardona P.J., Stanford J.L., van der Werf T.S. Therapeutic vaccines for tuberculosis - a systematic review. Vaccine 2014, 32:3162-3168.
50. Gil O., Diaz I., Vilaplana C., Tapia G., Diaz J., Fort M., et al. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS ONE 2010, 5:e10030.
51. Vilaplana C., Montane E., Pinto S., Barriocanal A.M., Domenech G., Torres F., et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010, 28:1106-1116.
52. Nell A.S., D'Lom E., Bouic P., Sabate M., Bosser R., Picas J., et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLOS ONE 2014, 9:e89612.
53. Ferraris D.M., Sbardella D., Petrera A., Marini S., Amstutz B., Coletta M., et al. Crystal structure of Mycobacterium tuberculosis zinc-dependent metalloprotease-1 (Zmp1), a metalloprotease involved in pathogenicity. J Biol Chem 2011, 286:32475-32482.
54. Petrera A., Amstutz B., Gioia M., Hahnlein J., Baici A., Selchow P., et al. Functional characterization of the Mycobacterium tuberculosis zinc metallopeptidase Zmp1 and identification of potential substrates. Biol Chem 2012, 393:631-640.
55. Master S.S., Rampini S.K., Davis A.S., Keller C., Ehlers S., Springer B., et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 2008, 3:224-232.
56. Johansen P., Fettelschoss A., Amstutz B., Selchow P., Waeckerle-Men Y., Keller P., et al. Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens. Clin Vaccine Immunol 2011, 18:907-913.
57. Sander P., Clark S., Petrera A., Vilaplana C., Meuli M., Selchow P., et al. Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis. Vaccine 2015.
58. Khatri B., Whelan A., Clifford D., Petrera A., Sander P., Vordermeier H.M. BCG Deltazmp1 vaccine induces enhanced antigen specific immune responses in cattle. Vaccine 2014, 32:779-784.
59. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
60. Marais B.J., Gie R.P., Schaaf H.S., Hesseling A.C., Obihara C.C., Nelson L.J., et al. The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004, 8:278-285.
61. Marais B.J., Gie R.P., Schaaf H.S., Hesseling A.C., Enarson D.A., Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006, 10:732-738.
62. Merle C.S., Cunha S.S., Rodrigues L.C. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010, 9:209-222.
63. Aaby P., Roth A., Ravn H., Napirna B.M., Rodrigues A., Lisse I.M., et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period. J Infect Dis 2011, 204:245-252.
64. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008, 5:e145.
65. Nunes-Alves C., Booty M.G., Carpenter S.M., Jayaraman P., Rothchild A.C., Behar S.M. In search of a new paradigm for protective immunity to TB. Nat Rev Microbiol 2014, 12:289-299.
66. Jensen K.J., Larsen N., Biering-Sørensen S., Andersen A., Eriksen H.B., Monteiro I., et al. Heterologous immunological effects of early BCG vaccination in low-birth weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis 2014, 10.1093/infdis/jiu508.
67. Benn C.S., Netea M.G., Selin L.K., Aaby P. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 2013, 34:431-439.
68. Soares A.P., Kwong Chung C.K., Choice T., Hughes E.J., Jacobs G., van Rensburg E.J., et al. Longitudinal changes in CD4+ T cell memory responses Induced by Bacille Calmette Guerin vaccination of newborns. J Infect Dis 2013.
69. Fletcher H.A., Tanner R., Wallis R.S., Meyer J., Manjaly Z-R., Harris S., et al. Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. Clin Vaccine Immunol 2013, 20:1683-1689.
70. Kleinnijenhuis J., Quintin J., Preijers F., Joosten L.A., Ifrim D.C., Saeed S., et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012, 109:17537-17542.